Recommendation of the President – Cibinqo (abrocitinib)

On 26 June 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 76/2025 on the appraisal of drug Cibinqo (abrocitinib), under drug program B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)”

Publication in Public Information Bulletin (BIP) >>